Atul Kantilal Patel

Atul Kantilal Patel

Auto-generated profile, based on publicly available information

Atul Kantilal Patel

Infectious Diseases Department, Sterling Hospital, Ahmedabad, India

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Journal of Critical Care
Verified
Journal Article
Closed access
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
HKHarsimran Kaur
Harsimran Kaur
JSJayanthi Savio
Jayanthi Savio
SRShivaprakash Rudramurthy
Shivaprakash Rudramurthy
APAtul Patel
Atul Patel
RARitesh Agarwal
Ritesh Agarwal

17 July 2020 in Mycoses
Verified
Journal Article
Closed access
PDF file
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
PSPrashant Sood
Prashant Sood
SRShivaprakash Rudramurthy
Shivaprakash Rudramurthy
SCSharon Chen
Sharon Chen
JJJoseph Jillwin
Joseph Jillwin
FNFor The Siham Candidemia Network
For The Siham Candidemia Network

19 September 2018 in Mycoses
Verified
Journal Article
Open access
PDF file
SLShang yi Lin
Shang yi Lin
LPLu Po-Liang
Lu Po-Liang
BTBan Hock Tan
Ban Hock Tan
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
UWUn‐In Wu
Un‐In Wu
T(the Asia Fungal Working Group (AFWG)
the Asia Fungal Working Group (AFWG)
Summary: Background: Current guidelines recommend echinocandins as first‐line therapy for candidemia. However, several non‐Candida yeast are non‐susceptible to echinocandins (echinocandin non‐susceptible yeast, ENSY), including Cryptococcus, Geotrichum, Malassezia, Pseudozyma, Rhodotorula, Saprochaete, Sporobolomyces and Trichosporon. In laboratories that are not equipped with rapid diagnostic tools, it often takes several days to identify yeast, and this may lead to inappropriate presumptive use of echinocandins in patients with ENSY fungemia. The aim of this study was to determine the distribution of ENSY species during a 1‐year, laboratory surveillance programme in Asia.Methods: Non‐duplicate yeast isolated from blood or bone marrow cultures at 25 hospitals in China, Hong Kong, India, Singapore, Taiwan and Thailand were analysed. Isolates were considered to be duplicative if they were obtained within 7 days from the same patient.Results: Of 2155 yeast isolates evaluated, 175 (8.1%) were non‐Candida yeast. The majority of non‐Candida yeast were ENSY (146/175, 83.4%). These included Cryptococcus (109 isolates), Trichosporon (23), Rhodotorula (10) and Malassezia (4). The proportion of ENSY isolates (146/2155, 6.7%) differed between tropical (India, Thailand and Singapore; 51/593, 8.6%) and non‐tropical countries/regions (China, Hong Kong and Taiwan; 95/1562, 6.1%, P = 0.038). ENSY was common in outpatient clinics (25.0%) and emergency departments (17.8%) but rare in intensive care units (4.7%) and in haematology‐oncology units (2.9%). Cryptococcus accounted for the majority of the non‐Candida species in emergency departments (21/24, 87.5%) and outpatient clinics (4/5, 80.0%).Conclusions: Isolation of non‐Candida yeast from blood cultures was not rare, and the frequency varied among medical units and countries.

9 December 2023 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
VMValliappan Muthu
Valliappan Muthu
RARitesh Agarwal
Ritesh Agarwal
SRShivaprakash Mandya Rudramurthy
Shivaprakash Mandya Rudramurthy
DTDeepak Thangaraju
Deepak Thangaraju
MSManoj Radhakishan Shevkani
Manoj Radhakishan Shevkani
ACArunaloke Chakrabarti
Arunaloke Chakrabarti

1 January 2020 in Indian Journal of Medical Microbiology
Verified
Journal Article
Open access
APAtul Patel
Atul Patel
KSKinjal Shah
Kinjal Shah
MDMitkumar Dharsandiya
Mitkumar Dharsandiya
KPKetan Patel
Ketan Patel
TPTushar Patel
Tushar Patel
AKAmbuj Kumar
Ambuj Kumar
Background: Cytokine release storm (CRS) in severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is thought to be the cause for organ damage and death which is independent of the actual viral burden. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, is approved for the treatment of CRS. We describe the efficacy and safety of TCZ in SARS CoV-2 pneumonia. Methods: This retrospective study was conducted at a tertiary care hospital from April 20 2020 to May 21 2020. The primary endpoint was the cumulative incidence of a composite of either need for admission to the intensive care unit (ICU) with invasive mechanical ventilation or death. Safety outcomes included an increase in liver transaminases and/or evidence of infection. Results: A total of 20 patients received TCZ during the study period. The median age was 54 years (95% confidence interval [CI] 47–63). About 85% of the patients were male. Nearly 70% of the patients had at least one comorbidity. About 55% required ICU admission. The median duration of ICU stay was 11 days (95% CI: 3–13 days). The cumulative incidence of the requirement for mechanical ventilation, clinical improvement and mortality was 11% (95% CI: 0.03%–1%), 74% (95% CI 37%–89%) and 25% (95% CI: 11%–63%), respectively. There was no difference in outcomes according to age, gender or computed tomography severity score. Asymptomatic transaminitis was the most common drug reaction (55%), and one patient developed bacteraemia. Conclusions: TCZ is likely a safe and effective modality of treatment for improving clinical and laboratory parameters of SARS CoV-2 patients with a reduction in ICU stay and ventilatory care need.

9 March 2017 in Mycoses
Verified
Journal Article
Closed access
PDF file
APAtul K. Patel
Atul K. Patel
KPKetan K. Patel
Ketan K. Patel
KPKamlesh Patel
Kamlesh Patel
SGSwati Gohel
Swati Gohel
ACArunaloke Chakrabarti
Arunaloke Chakrabarti